- Home
- SG vs IRON Comparison
SG vs IRON Comparison
Compare SG & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SG
- IRON
- Stock Information
- Founded
- SG 2007
- IRON 2017
- Country
- SG United States
- IRON United States
- Employees
- SG N/A
- IRON N/A
- Industry
- SG Restaurants
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- SG Consumer Discretionary
- IRON Health Care
- Exchange
- SG Nasdaq
- IRON Nasdaq
- Market Cap
- SG 1.8B
- IRON 1.8B
- IPO Year
- SG 2021
- IRON N/A
- Fundamental
- Price
- SG $13.30
- IRON $55.86
- Analyst Decision
- SG Buy
- IRON Strong Buy
- Analyst Count
- SG 14
- IRON 11
- Target Price
- SG $24.69
- IRON $92.64
- AVG Volume (30 Days)
- SG 5.2M
- IRON 390.2K
- Earning Date
- SG 08-07-2025
- IRON 08-07-2025
- Dividend Yield
- SG N/A
- IRON N/A
- EPS Growth
- SG N/A
- IRON N/A
- EPS
- SG N/A
- IRON N/A
- Revenue
- SG $685,280,000.00
- IRON N/A
- Revenue This Year
- SG $13.88
- IRON N/A
- Revenue Next Year
- SG $19.96
- IRON N/A
- P/E Ratio
- SG N/A
- IRON N/A
- Revenue Growth
- SG 11.10
- IRON N/A
- 52 Week Low
- SG $11.86
- IRON $30.82
- 52 Week High
- SG $45.12
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- SG 45.89
- IRON 61.10
- Support Level
- SG $12.94
- IRON $52.70
- Resistance Level
- SG $15.07
- IRON $55.26
- Average True Range (ATR)
- SG 0.87
- IRON 2.42
- MACD
- SG 0.16
- IRON 0.01
- Stochastic Oscillator
- SG 45.52
- IRON 92.71
About SG Sweetgreen Inc.
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.